MX2020002995A - Metodo de conjugacion de transglutaminasa y ligador. - Google Patents
Metodo de conjugacion de transglutaminasa y ligador.Info
- Publication number
- MX2020002995A MX2020002995A MX2020002995A MX2020002995A MX2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A MX 2020002995 A MX2020002995 A MX 2020002995A
- Authority
- MX
- Mexico
- Prior art keywords
- sub
- aax
- linker
- amino acid
- conjugation method
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Wood Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a un método para generar un conjugado de anticuerpo-carga útil por medio de una transglutaminasa microbiana (MTG). El método comprende un paso para conjugar un ligador que tiene un residuo de amina primaria, el ligador tiene la estructura de péptido (mostrada en la dirección N->C) (Aax)m-(Aax)(NH2)-(Aax)n-B-(Aax)o, o (Aax)m-B-(Aax)n-(Aax)(NH2)-(Aax)o, a un residuo Gln comprendido en la cadena pesada o ligera de un anticuerpo. Aax(NH2) es un aminoácido, derivado de aminoácido o mimético de aminoácido que comprende una cadena lateral que tiene un grupo amina primaria (Figura 1).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17191825 | 2017-09-19 | ||
GBGB1800878.9A GB201800878D0 (en) | 2018-01-19 | 2018-01-19 | Transglutaminase conjugation method and linker |
PCT/EP2018/075350 WO2019057772A1 (en) | 2017-09-19 | 2018-09-19 | METHOD FOR CONJUGATING TRANSGLUTAMINASE AND BINDING SEQUENCE |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2020002995A true MX2020002995A (es) | 2020-07-22 |
Family
ID=63678617
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2020002995A MX2020002995A (es) | 2017-09-19 | 2018-09-19 | Metodo de conjugacion de transglutaminasa y ligador. |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210128743A1 (es) |
EP (1) | EP3684419A1 (es) |
JP (1) | JP2020534030A (es) |
KR (1) | KR20200057046A (es) |
CN (1) | CN111163809A (es) |
AU (1) | AU2018337671B2 (es) |
CA (2) | CA3075218A1 (es) |
MX (1) | MX2020002995A (es) |
NZ (1) | NZ762376A (es) |
WO (1) | WO2019057772A1 (es) |
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115916832A (zh) * | 2020-05-20 | 2023-04-04 | 詹森生物科技公司 | 含有糖基化Fc结构域的蛋白质的位点特异性缀合的方法 |
KR20230069211A (ko) | 2020-09-18 | 2023-05-18 | 아라리스 바이오테크 아게 | 아미노산-기반 링커를 사용한 트란스글루타미나제 접합 방법 |
KR20230096052A (ko) | 2020-10-25 | 2023-06-29 | 아라리스 바이오테크 아게 | 항체-링커 접합체를 생성하기 위한 수단 및 방법 |
US20230181754A1 (en) | 2021-07-09 | 2023-06-15 | Bright Peak Therapeutics Ag | Modified checkpoint inhibitors and uses thereof |
WO2023281483A1 (en) | 2021-07-09 | 2023-01-12 | Bright Peak Therapeutics Ag | Modified tnf-antibodies and uses thereof |
EP4366781A1 (en) | 2021-07-09 | 2024-05-15 | Bright Peak Therapeutics AG | Checkpoint inhibitors conjugated to il-2, and uses thereof |
AU2022306145A1 (en) | 2021-07-09 | 2024-02-01 | Bright Peak Therapeutics Ag | Antibody conjugates and manufacture thereof |
US20230201365A1 (en) | 2021-07-09 | 2023-06-29 | Bright Peak Therapeutics Ag | Modified cd20 antibodies and uses thereof |
CA3234692A1 (en) * | 2021-09-30 | 2023-04-06 | Ajinomoto Co., Inc. | Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound used in production of the same or salts thereof |
WO2023072934A1 (en) | 2021-10-25 | 2023-05-04 | Araris Biotech Ag | Methods for producing antibody-linker conjugates |
WO2023161296A1 (en) * | 2022-02-22 | 2023-08-31 | Adc Therapeutics Sa | Conjugation method involving a transglutaminase at the fc region comprising a trimmed n-glycan |
WO2023161291A1 (en) | 2022-02-22 | 2023-08-31 | Araris Biotech Ag | Peptide linkers comprising two or more payloads |
WO2023161854A1 (en) * | 2022-02-23 | 2023-08-31 | Bright Peak Therapeutics Ag | Immune antigen specific il-18 immunocytokines and uses thereof |
WO2023170239A1 (en) | 2022-03-09 | 2023-09-14 | Merck Patent Gmbh | Methods and tools for conjugation to antibodies |
WO2023225666A1 (en) * | 2022-05-20 | 2023-11-23 | Curie Co. Inc. | Pro-peptide variants for modulating activity of transglutaminases |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994012520A1 (en) * | 1992-11-20 | 1994-06-09 | Enzon, Inc. | Linker for linked fusion polypeptides |
JP2005507650A (ja) * | 2001-08-01 | 2005-03-24 | セロミックス インコーポレイテッド | 新規融合タンパク質及び分子結合に関するアッセイ |
US6660510B2 (en) | 2001-12-17 | 2003-12-09 | Food Industry Research And Development | Transglutaminase gene of Streptoverticillium ladakanum and the transglutaminase encoded therefrom |
WO2008099898A1 (ja) | 2007-02-15 | 2008-08-21 | Ajinomoto Co., Inc. | ジスルフィド結合導入トランスグルタミナーゼ |
EP2121744A1 (en) | 2007-02-22 | 2009-11-25 | Novo Nordisk Health Care AG | Transglutaminase variants with improved specificity |
WO2011119484A1 (en) * | 2010-03-23 | 2011-09-29 | Iogenetics, Llc | Bioinformatic processes for determination of peptide binding |
CA2930801C (en) * | 2010-11-05 | 2019-05-28 | Rinat Neuroscience Corporation | Engineered polypeptide conjugates and methods for making thereof using transglutaminase |
EP2771349B1 (en) * | 2011-09-16 | 2020-02-26 | Iogenetics, LLC. | Bioinformatic processes for determination of peptide binding |
WO2013049830A2 (en) * | 2011-09-30 | 2013-04-04 | The Washington University | Tip-1 and grp-78 binding peptides and method of identifying peptide receptors |
US9717803B2 (en) | 2011-12-23 | 2017-08-01 | Innate Pharma | Enzymatic conjugation of polypeptides |
WO2014009426A2 (en) * | 2012-07-13 | 2014-01-16 | Innate Pharma | Screening of conjugated antibodies |
KR20160042871A (ko) * | 2013-06-21 | 2016-04-20 | 이나뜨 파르마, 에스.아. | 폴리펩티드의 효소적 콘쥬게이션 |
JP6521959B2 (ja) | 2013-07-31 | 2019-05-29 | ライナット ニューロサイエンス コーポレイション | 操作されたポリペプチドコンジュゲート |
SI3134127T1 (sl) * | 2014-04-25 | 2020-06-30 | Rinat Neuroscience Corp. | Konjugati zdravil s protitelesi z visoko stopnjo zdravila |
JP6666336B2 (ja) | 2014-06-12 | 2020-03-13 | シー・エス・ピー・シー ドフェン コーポレーションCspc Dophen Corporation | 酵素的方法による均一抗体薬物コンジュゲート |
PE20180452A1 (es) * | 2015-06-23 | 2018-03-05 | Bayer Pharma AG | Conjugados homogeneos especificos de sitio con inhibidores de ksp |
AU2016306907A1 (en) | 2015-08-07 | 2018-03-29 | Merck Patent Gmbh | A transglutamine tag for efficient site-specific bioconjugation |
AU2017336546A1 (en) * | 2016-09-27 | 2019-05-02 | Epicentrx, Inc. | Immunomodulatory fusion proteins |
-
2018
- 2018-09-19 CN CN201880060599.4A patent/CN111163809A/zh active Pending
- 2018-09-19 US US16/648,636 patent/US20210128743A1/en active Pending
- 2018-09-19 NZ NZ762376A patent/NZ762376A/en unknown
- 2018-09-19 AU AU2018337671A patent/AU2018337671B2/en active Active
- 2018-09-19 CA CA3075218A patent/CA3075218A1/en active Pending
- 2018-09-19 JP JP2020537053A patent/JP2020534030A/ja active Pending
- 2018-09-19 WO PCT/EP2018/075350 patent/WO2019057772A1/en unknown
- 2018-09-19 CA CA3177215A patent/CA3177215A1/en active Pending
- 2018-09-19 MX MX2020002995A patent/MX2020002995A/es unknown
- 2018-09-19 EP EP18773746.5A patent/EP3684419A1/en active Pending
- 2018-09-19 KR KR1020207011370A patent/KR20200057046A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA3075218A1 (en) | 2019-03-28 |
JP2020534030A (ja) | 2020-11-26 |
CA3177215A1 (en) | 2019-03-28 |
AU2018337671A1 (en) | 2020-03-26 |
NZ762376A (en) | 2022-08-26 |
CN111163809A (zh) | 2020-05-15 |
EP3684419A1 (en) | 2020-07-29 |
AU2018337671B2 (en) | 2021-03-04 |
WO2019057772A1 (en) | 2019-03-28 |
US20210128743A1 (en) | 2021-05-06 |
KR20200057046A (ko) | 2020-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2020002995A (es) | Metodo de conjugacion de transglutaminasa y ligador. | |
CY1120249T1 (el) | Αντισωμα ανταγωνιστης κατευθυνομενο εναντι πεπτιδιου σχετιζομενου με το γονιδιο καλσιτονινης | |
CU20190099A7 (es) | Dominio de unión a antígeno anti-trbc1, y receptor de antígeno quimérico, anticuerpo, acoplador biespecífico de células t y conjugado anticuerpo-fármaco que comprenden el mismo | |
AR110853A2 (es) | Un método para preparar el conjugado de péptido insulinotrópico, y una composición farmacéutica que comprende a dicho conjugado de péptido insulinotrópico | |
RS54468B1 (en) | MONOCLONAL ANTIBODIES AGAINST CLAUDINE-18 FOR THE CANCER TREATMENT | |
EA201892007A1 (ru) | 3-дезоксипроизводное и фармацевтические композиции на его основе | |
AR065083A1 (es) | Hepcidina, antagonistas de la hepcidina y metodos de uso | |
ATE412688T1 (de) | Hochfunktionelle, hochverzweigte polyharnstoffe | |
NZ610239A (en) | Cross-linkers and their uses | |
CO6180445A2 (es) | Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3 | |
DK1423419T3 (da) | Hybrid- og tandemekspression af Neisseria-proteiner | |
CY1116632T1 (el) | Εξουδετερωτες αντισωματων του τελεστη διεγερσης αποικιων κοκκιοκυτταρων μακροφαγων ανθρωπου | |
AR070202A1 (es) | Anticuerpos anti- trkb mejorados | |
PH12014501783B1 (en) | Anti-lipoarabinomannan antibody and immunoassay for acid-fast bacillary infection using the antibody | |
AR058419A1 (es) | Compuestos de nucleosidos triciclicos para tratar infecciones virales | |
CR10273A (es) | "anticuerpos anti-5t4 y usos de los mismos" | |
CY1114504T1 (el) | Συνθεσεις τιγεκυκλινης και μεθοδοι παρασκευης | |
MX338940B (es) | Identificacion de epitopos ige novedosos. | |
EA201590627A1 (ru) | Антитела, распознающие альфа-синуклеин | |
CY1110651T1 (el) | Παραγωγα της ν-'(1,5-διφαινυλ-1η- πυραζολ-3-υλ)μεθυλ σουλφοναμιδης με μια συγγενεια για τους υποδοχεις cb1 | |
RS54299B1 (en) | COMPOSITIONS AND METHODS OF USING THERAPY ANTIBODIES | |
GT200100008A (es) | Compuesto anticanceroso y metodo de separacion de enantiomeros util para sintetizar dicho compuesto. | |
ATE405603T1 (de) | Hochfunktionelle, hochverzweigte polyharnstoffe | |
EA200870208A1 (ru) | Конструкт однодоменного антитела | |
CY1108321T1 (el) | Καινοφανη παραγωγα δικαρβοξυλικου οξεος |